CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection

Area of Science:

• Immunology
• Molecular Biology
• Cancer Biology

Background:

• The oncoprotein Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is overexpressed in many cancers.
• CIP2A's role in normal immune function and its mechanism of inhibiting Protein Phosphatase 2A (PP2A) are not well understood.
• PP2A is known to regulate immune responses.

Purpose of the Study:

• To investigate the physiological importance of CIP2A in immune system development and response.
• To determine the role of CIP2A in T-cell activation and adaptive immunity.
• To explore the potential of CIP2A as a therapeutic target in cancer without causing immunological side-effects.

Main Methods:

• Utilized CIP2A-deficient mice (CIP2AHOZ) to study immune responses under normal and challenged conditions.
• Infection with Listeria monocytogenes to assess adaptive immune response.
• Flow cytometry to analyze T-cell populations (CD4+ and CD8+).
• Investigated cell-autonomous effects of CIP2A deficiency on T-cell activation and its dependence on Zap70 activity.

Main Results:

• CIP2A-deficient mice exhibit normal immune development and function without challenges.
• Upon Listeria monocytogenes infection, CIP2AHOZ mice show impaired adaptive immunity with reduced CD4+ and CD8+ effector T-cells.
• CIP2A deficiency directly impacts T-cell activation in a cell-autonomous manner.
• CIP2A expression during T-cell activation is dependent on Zap70 activity.

Conclusions:

• CIP2A is a previously unrecognized mediator of T-cell activation in adaptive immune responses.
• CIP2A-deficient mice serve as a valuable model for studying PP2A's role in immune regulation.
• Targeting CIP2A for cancer therapy is unlikely to cause significant immunological side-effects.